Development of humoral and cellular immunological memory against SARS-CoV-2 despite B cell depleting treatment in multiple sclerosis
Summary: B cell depleting therapies (BCDTs) are widely used as immunomodulating agents for autoimmune diseases such as multiple sclerosis. Their possible impact on development of immunity to severe acute respiratory syndrome virus-2 (SARS-CoV-2) has raised concerns with the coronavirus disease 2019...
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-09-01
|
Series: | iScience |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2589004221010464 |
id |
doaj-e843238deb42433aab6c256004b1505d |
---|---|
record_format |
Article |
spelling |
doaj-e843238deb42433aab6c256004b1505d2021-09-25T05:10:39ZengElsevieriScience2589-00422021-09-01249103078Development of humoral and cellular immunological memory against SARS-CoV-2 despite B cell depleting treatment in multiple sclerosisKlara Asplund Högelin0Nicolas Ruffin1Elisa Pin2Anna Månberg3Sophia Hober4Guro Gafvelin5Hans Grönlund6Peter Nilsson7Mohsen Khademi8Tomas Olsson9Fredrik Piehl10Faiez Al Nimer11Neuroimmunology Unit, Department of Clinical Neuroscience, Karolinska Institutet, Center for Molecular Medicine L8:04, 171 76 Stockholm, SwedenNeuroimmunology Unit, Department of Clinical Neuroscience, Karolinska Institutet, Center for Molecular Medicine L8:04, 171 76 Stockholm, SwedenDivision of Affinity Proteomics, Department of Protein Science, KTH Royal Institute of Technology, SciLifeLab, 17165 Stockholm, SwedenDivision of Affinity Proteomics, Department of Protein Science, KTH Royal Institute of Technology, SciLifeLab, 17165 Stockholm, SwedenDivision of Protein Technology, Department of Protein Science, KTH Royal Institute of Technology, SciLifeLab, 17165 Stockholm, SwedenTherapeutic Immune Design Unit, Department of Clinical Neuroscience, Karolinska Institutet, Center for Molecular Medicine L8:02, 171 76 Stockholm, SwedenTherapeutic Immune Design Unit, Department of Clinical Neuroscience, Karolinska Institutet, Center for Molecular Medicine L8:02, 171 76 Stockholm, SwedenDivision of Affinity Proteomics, Department of Protein Science, KTH Royal Institute of Technology, SciLifeLab, 17165 Stockholm, SwedenNeuroimmunology Unit, Department of Clinical Neuroscience, Karolinska Institutet, Center for Molecular Medicine L8:04, 171 76 Stockholm, SwedenNeuroimmunology Unit, Department of Clinical Neuroscience, Karolinska Institutet, Center for Molecular Medicine L8:04, 171 76 Stockholm, SwedenNeuroimmunology Unit, Department of Clinical Neuroscience, Karolinska Institutet, Center for Molecular Medicine L8:04, 171 76 Stockholm, SwedenNeuroimmunology Unit, Department of Clinical Neuroscience, Karolinska Institutet, Center for Molecular Medicine L8:04, 171 76 Stockholm, Sweden; Corresponding authorSummary: B cell depleting therapies (BCDTs) are widely used as immunomodulating agents for autoimmune diseases such as multiple sclerosis. Their possible impact on development of immunity to severe acute respiratory syndrome virus-2 (SARS-CoV-2) has raised concerns with the coronavirus disease 2019 (COVID-19) pandemic. We here evaluated the frequency of COVID-19-like symptoms and determined immunological responses in participants of an observational trial comprising several multiple sclerosis disease modulatory drugs (COMBAT-MS; NCT03193866) and in eleven patients after vaccination, with a focus on BCDT. Almost all seropositive and 17.9% of seronegative patients on BCDT, enriched for a history of COVID-19-like symptoms, developed anti-SARS-CoV-2 T cell memory, and T cells displayed functional similarity to controls producing IFN-γ and TNF. Following vaccination, vaccine-specific humoral memory was impaired, while all patients developed a specific T cell response. These results indicate that BCDTs do not abrogate SARS-CoV-2 cellular memory and provide a possible explanation as to why the majority of patients on BCDTs recover from COVID-19.http://www.sciencedirect.com/science/article/pii/S2589004221010464ImmunologyVirology |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Klara Asplund Högelin Nicolas Ruffin Elisa Pin Anna Månberg Sophia Hober Guro Gafvelin Hans Grönlund Peter Nilsson Mohsen Khademi Tomas Olsson Fredrik Piehl Faiez Al Nimer |
spellingShingle |
Klara Asplund Högelin Nicolas Ruffin Elisa Pin Anna Månberg Sophia Hober Guro Gafvelin Hans Grönlund Peter Nilsson Mohsen Khademi Tomas Olsson Fredrik Piehl Faiez Al Nimer Development of humoral and cellular immunological memory against SARS-CoV-2 despite B cell depleting treatment in multiple sclerosis iScience Immunology Virology |
author_facet |
Klara Asplund Högelin Nicolas Ruffin Elisa Pin Anna Månberg Sophia Hober Guro Gafvelin Hans Grönlund Peter Nilsson Mohsen Khademi Tomas Olsson Fredrik Piehl Faiez Al Nimer |
author_sort |
Klara Asplund Högelin |
title |
Development of humoral and cellular immunological memory against SARS-CoV-2 despite B cell depleting treatment in multiple sclerosis |
title_short |
Development of humoral and cellular immunological memory against SARS-CoV-2 despite B cell depleting treatment in multiple sclerosis |
title_full |
Development of humoral and cellular immunological memory against SARS-CoV-2 despite B cell depleting treatment in multiple sclerosis |
title_fullStr |
Development of humoral and cellular immunological memory against SARS-CoV-2 despite B cell depleting treatment in multiple sclerosis |
title_full_unstemmed |
Development of humoral and cellular immunological memory against SARS-CoV-2 despite B cell depleting treatment in multiple sclerosis |
title_sort |
development of humoral and cellular immunological memory against sars-cov-2 despite b cell depleting treatment in multiple sclerosis |
publisher |
Elsevier |
series |
iScience |
issn |
2589-0042 |
publishDate |
2021-09-01 |
description |
Summary: B cell depleting therapies (BCDTs) are widely used as immunomodulating agents for autoimmune diseases such as multiple sclerosis. Their possible impact on development of immunity to severe acute respiratory syndrome virus-2 (SARS-CoV-2) has raised concerns with the coronavirus disease 2019 (COVID-19) pandemic. We here evaluated the frequency of COVID-19-like symptoms and determined immunological responses in participants of an observational trial comprising several multiple sclerosis disease modulatory drugs (COMBAT-MS; NCT03193866) and in eleven patients after vaccination, with a focus on BCDT. Almost all seropositive and 17.9% of seronegative patients on BCDT, enriched for a history of COVID-19-like symptoms, developed anti-SARS-CoV-2 T cell memory, and T cells displayed functional similarity to controls producing IFN-γ and TNF. Following vaccination, vaccine-specific humoral memory was impaired, while all patients developed a specific T cell response. These results indicate that BCDTs do not abrogate SARS-CoV-2 cellular memory and provide a possible explanation as to why the majority of patients on BCDTs recover from COVID-19. |
topic |
Immunology Virology |
url |
http://www.sciencedirect.com/science/article/pii/S2589004221010464 |
work_keys_str_mv |
AT klaraasplundhogelin developmentofhumoralandcellularimmunologicalmemoryagainstsarscov2despitebcelldepletingtreatmentinmultiplesclerosis AT nicolasruffin developmentofhumoralandcellularimmunologicalmemoryagainstsarscov2despitebcelldepletingtreatmentinmultiplesclerosis AT elisapin developmentofhumoralandcellularimmunologicalmemoryagainstsarscov2despitebcelldepletingtreatmentinmultiplesclerosis AT annamanberg developmentofhumoralandcellularimmunologicalmemoryagainstsarscov2despitebcelldepletingtreatmentinmultiplesclerosis AT sophiahober developmentofhumoralandcellularimmunologicalmemoryagainstsarscov2despitebcelldepletingtreatmentinmultiplesclerosis AT gurogafvelin developmentofhumoralandcellularimmunologicalmemoryagainstsarscov2despitebcelldepletingtreatmentinmultiplesclerosis AT hansgronlund developmentofhumoralandcellularimmunologicalmemoryagainstsarscov2despitebcelldepletingtreatmentinmultiplesclerosis AT peternilsson developmentofhumoralandcellularimmunologicalmemoryagainstsarscov2despitebcelldepletingtreatmentinmultiplesclerosis AT mohsenkhademi developmentofhumoralandcellularimmunologicalmemoryagainstsarscov2despitebcelldepletingtreatmentinmultiplesclerosis AT tomasolsson developmentofhumoralandcellularimmunologicalmemoryagainstsarscov2despitebcelldepletingtreatmentinmultiplesclerosis AT fredrikpiehl developmentofhumoralandcellularimmunologicalmemoryagainstsarscov2despitebcelldepletingtreatmentinmultiplesclerosis AT faiezalnimer developmentofhumoralandcellularimmunologicalmemoryagainstsarscov2despitebcelldepletingtreatmentinmultiplesclerosis |
_version_ |
1717368932231282688 |